Clinical Trials Browser

Completed × Carcinoma, Hepatocellular × camrelizumab × Clear all

NCT05003700 2024-11-05

Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT04627012 2024-03-06

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases